NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT04442581 2023-04-05Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver CancerUniversity of WashingtonPhase 2 Terminated2 enrolled 12 charts